Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights

Ayrton I Bangolo,Chinmay Trivedi,Ishan Jani,Silvanna Pender,Hirra Khalid,Budoor Alqinai,Alina Intisar,Karamvir Randhawa,Joseph Moore,Nicoleta De Deugd,Shaji Faisal,Suchith Boodgere Suresh,Parva Gopani,Vignesh K Nagesh,Tracy Proverbs-Singh,Simcha Weissman
DOI: https://doi.org/10.3748/wjg.v29.i25.3984
IF: 5.374
2023-07-07
World Journal of Gastroenterology
Abstract:The gut microbiome plays an important role in the variation of pharmacologic response. This aspect is especially important in the era of precision medicine, where understanding how and to what extent the gut microbiome interacts with drugs and their actions will be key to individualizing therapy. The impact of the composition of the gut microbiome on the efficacy of newer cancer therapies such as immune checkpoint inhibitors and chimeric antigen receptor T-cell treatment has become an active area of research. Pancreatic adenocarcinoma (PAC) has a poor prognosis even in those with potentially resectable disease, and treatment options are very limited. Newer studies have concluded that there is a synergistic effect for immunotherapy in combination with cytotoxic drugs, in the treatment of PAC. A variety of commensal microbiota can affect the efficacy of conventional chemotherapy and immunotherapy by modulating the tumor microenvironment in the treatment of PAC. This review will provide newer insights on the impact that alterations made in the gut microbial system have in the development and treatment of PAC.
gastroenterology & hepatology
What problem does this paper attempt to address?